The Impact of New National Guidelines on Screening for Gestational Diabetes Mellitus

Abstract:
FM Ali, N Farah, V O’Dwyer, C O’Connor, MM Kennedy, MJ Turner
UCD Centre for Human Reproduction, Coombe Women and Infants University Hospital, Dublin 8

Abstract
Gestational diabetes mellitus (GDM) has important maternal and fetal implications. In 2010, the Health Service Executive published the impact of the new guidelines in a large maternity unit. In January 2011, the hospital replaced the 100g Oral Glucose Tolerance Test (OGTT) with the new 75g OGTT. We compared the first 6 months of 2011 with the first 6 months of 2010. The new guidelines were associated with an increase in OGTTs performed from 1375 in the first half of 2010 to 1679 in the first half of 2011 (a 22% increase) (p<0.001). Of the women screened, the number of abnormal OGTTs increased from 10.1%(n=139) in 2010 to 13.2% (n=221) in 2011 (p<0.001). The combination of increased screening and a more sensitive OGTT resulted in the number of women diagnosed with GDM increasing 59% from 139 to 221 (p=0.02). This large increase has important resource implications but, if clinical outcomes are improved, there should be a decrease in long-term costs.

Introduction
The diagnosis of gestational diabetes mellitus (GDM) carries lifelong consequences for the mother and her offspring. It is associated with an increase in perinatal complications, including fetal macrosomia and neonatal hypoglycaemia. It is also associated with increased obstetric interventions such as induction of labour and cesarean section, which may in turn increase maternal morbidity. In the long term it increases the risk of metabolic syndrome for both mother and baby, which may manifest itself later in life in the form of diabetes mellitus or cardiovascular disease. International consensus about screening for GDM has been difficult to achieve. Some experts, for example, advocate universal screening, others selective. Some advocate using an Oral Glucose Tolerance Test (OGTT) with a 100g glucose load. Using a 75g OGTT is based on the subsequent likelihood of developing adult-onset diabetes mellitus and was not predictive of any specific pregnancy outcomes. Recent studies, however, have reported that maternal hyperglycaemia, insufficient to make the diagnosis of GDM, is associated with adverse perinatal outcomes. As a result, an international consensus developed new lower diagnostic cut-off points in women for the diagnosis of GDM based on an odds ratio for adverse outcomes of e.75 compared with women with normal mean glucose levels. In 2010, the Health Services Executive (HSE) in Ireland published national guidelines for GDM incorporating the latest international evidence. The purpose of this study was to examine the impact of introducing the new guidelines in a large maternity unit.

Methods
As the new guidelines were published in August of 2010, we compared the results from the first 6 months of 2011 with the first 6 months of 2010. Screening was sent 6.1% based on risk factors and a 100g OGTT was used. The normal blood sugars were fasting <5.3 mmol/l, 1 hour < 10.0 mmol, 2 hour < 8.6 mmol and 3 hour <7.8 mmol. A diagnosis of GDM was made if two or more values were met or exceeded. From January 1st 2011, screening continued to be based on risk factors only. The normal blood sugars were fasting <5.1 mmol/l, 1 hour <10.0 mmol, 2 hour <8.5mmol. A diagnosis of GDM was made if one or more values were met or exceeded.

Results
The indications for the OGTT were based on the risk factors published in 2010 and are shown in Table 1. The number of women who delivered a baby weighing 500g or more was 4289 for the first 6 months of 2010 compared with 4184 in 2011. Approximately a third of women attending antenatally were screened on a selective basis. A combination of maternal obesity and family history had the highest incidence of abnormal OGTT at 23.4%. Of women screened, the incidence of GDM was 15.1% (n=78) out of 518 women >35 years, compared with 12.3% (n=143) out of 1161 women d 35 years (NS). The introduction of the national guidelines was associated with an increase in OGTTs performed from 1375 in the first half of 2010 to 1679 in the first half of 2011 (a 22% increase) (p<0.001). Of the women screened, the number of abnormal OGTTs increased from 10.1%(n=139) in 2010 to 13.2% (n=221) in 2011 (p<0.001). The combination of increased screening and a more sensitive OGTT resulted in the number of women diagnosed with GDM increasing from 139 to 221 (a 59% increase) (p=0.02). The number of fasting glucose tests deemed abnormal increased from 51 to 106 in 2011 at 116 in 2011 (a 127% increase, p<0.001). It follows that the number of women who should be referred postnatally for an OGTT to confirm that diabetes mellitus is not persistent will also need to increase by 59%.

Discussion
The introduction of new national guidelines in Ireland has resulted in a large increase in the number of women being diagnosed with GDM in our Hospital. The increase may be due, in part, to improved compliance with the indications for screening, but an increase is also to be expected because the threshold for diagnosis internationally has been lowered. Our results are similar to those reported from the West of Ireland. In a large national sample of pregnant women in the United States, it was concluded that the number of women diagnosed with GDM after the 75 g OGTT doubles in comparison with the number diagnosed with an 100g OGTT. Based on a 75 g OGTT at 24-28 weeks, 9.4% met the criteria for GDM using previous criteria but, 12.4%, met the criteria using the new national guidelines. In a large national sample of pregnant women in the United States, it was concluded that the number of women diagnosed with GDM after the 75 g OGTT doubles in comparison with the number diagnosed with an 100 g OGTT.

Apart from the increased direct cost of screening, this increase in the number of cases has resource implications. An increase in prevalence of GDM will increase demands for multidisciplinary care by midwives, dieticians, sonographers, obstetricians and neonatologists. There will also be an increase in direct costs for laboratory testing and pharmaceutical treatment in women with GDM. Potentially, it may lead to an increase in obstetric interventions such as induction of labour and caesarean section. It will also increase the number of women who require a postnatal OGTT to confirm that the OGTT has reverted back to normal. Potentially, it may increase service needs in primary care if a woman’s OGTT remains abnormal postpartum. The increase in the number of women diagnosed with GDM in 2011 may also be an underestimate. Previous studies based on either universal screening or selective screening have reported low compliance with guidelines. The increased diagnosis of GDM followed by appropriate interventions to optimise maternal glycaemia should bring clinical benefits to both mother and baby. Minimising hyperglycaemia should avoid fetal macrosomia and associated shoulder dystocia, which potentially may prevent permanent brachial plexus injury (BPI). This is important clinically and BPI often results in obstetric negligence cases, which are expensive for the maternity services whether successfully defended or not. There is also evidence that maternal hyperglycaemia increases not only fetal adiposity, but also may influence the distribution of fetal adipose tissue in utero. In the short-term, poorly controlled maternal hyperglycaemia may result in maternal hyperglycaemia and admission to the neonatal care unit and in the long-term is associated with an increased risk of childhood obesity, metabolic syndrome and diabetes mellitus in adulthood which has maternal implications. Fetal macrosomia may result in obstetric complications such as peripartum haemorrhage, increased risk of operative delivery, particularly caesarean section (CS). It may also increase the risk of induction of labour which itself is associated with an increased rate of CS. However, in an Australian multicentre randomised controlled trial, the rate of induction was higher in the treated GDM group, yet CS rates were nearly equivalent between the treated (31%) and untreated (32%) women. In the long term women who are more likely to develop DM later in life develop DM later in life in women with GDM underwent postpartum glucose testing.

The implementation of the new national guidelines and, in particular, the management of more women diagnosed with GDM will increase the costs of maternity care in the third trimester. If implementation leads to improved glycaemic control and to a decrease in adverse clinical outcomes for both mother and her baby then it is expected that the increased short-term investment will reap long-term financial as well as clinical dividends. We plan to follow-up the 2011 cohort screened to see if the increased diagnosis of GDM leads to a change in clinical outcomes, particularly fetal macrosomia.
Acknowledgements
We thank the midwifery staff in the Perinatal Centre and F Dunleavy, dietician for their assistance.

References